Skip to content

Study · Animal study (in vivo) · 1979

2 results

Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.

Chiu S, Mishra RK

European journal of pharmacology1 Jan 1979Cited by 39 (Europe PMC)

PMID32058 (opens in a new tab)DOI10.1016/0014-2999(79)90156-0 (opens in a new tab)PepBankPUB-00032058
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In an experimental catalepsy model, acute PLG slightly attenuated morphine-induced catalepsy.

    In plain wordsIn an experimental model, acute PLG slightly reduced morphine-induced catalepsy.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseCatalepsy after acute treatment
    Study

    n: not reported in source

    morphine-induced catalepsy
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 mg kg-1 · subcutaneousAs given in this study.

    Source sentences

    Summary
    Although acute administration of PLG (10 mg kg-1 s.c.) slightly attenuated the cataleptic response, chronic PLG treatment (10 mg kg-1 s.c. for 10 days) virtually abolished morphine-induced catalepsy.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an experimental catalepsy model, chronic PLG virtually abolished morphine-induced catalepsy.

    In plain wordsIn an experimental model, chronic PLG almost eliminated morphine-induced catalepsy.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseCatalepsy after chronic treatment
    Study

    n: not reported in source

    morphine-induced catalepsy
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10 mg kg-1 · subcutaneous · 10 daysAs given in this study.

    Source sentences

    Summary
    Although acute administration of PLG (10 mg kg-1 s.c.) slightly attenuated the cataleptic response, chronic PLG treatment (10 mg kg-1 s.c. for 10 days) virtually abolished morphine-induced catalepsy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.